Empowering mental health professionals with peer-reviewed psychiatric research and insights
Just Published
Original Research
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management
August 27, 2025
This study provides preliminary evidence that longitudinal use of an AI-enabled clinical decision support system can improve outcomes in MDD.
Original Research
N-acetylcysteine for Co-occurring PTSD and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial
August 27, 2025
Among individuals with PTSD and alcohol use disorder receiving CBT and either NAC or placebo, both groups had significant reductions in both PTSD symptom severity and alcohol use, with…
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to…
Clinical and Practical Psychopharmacology
The Superiority of Clozapine Over SGAs in Patients With Treatment-Resistant Schizophrenia
August 25, 2025
Clozapine is associated with many adverse effects. Given the findings that olanzapine and risperidone may be as good as clozapine in treatment-resistant schizophrenia (TRS), it may be worth trialing…
Vol 86 • 2025 • Number 2
Read the Current Issue
Original Research
Incidence and Risk Factors for Suicide Attempt During Pregnancy and Postpartum
Original Research
Valbenazine in Elderly Adults With Tardive Dyskinesia
Academic Highlights
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
Original Research
Older Adults Visiting Emergency Departments for Mental Health Issues:A CHIRPP Database Study
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations
Brief Report
Psychosocial Correlates of Optimism among US Military Veterans
Original Research
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Original Research
The Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
August 11, 2025
Medical Expenditure Panel Survey data showed that over half of adults with schizophrenia report cognitive impairments, which were associated with higher healthcare costs and lower quality of life.
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to…
Review Articles
Review Article
Cognitive Effects of ECT in Schizophrenia: A Review
June 5, 2024
ECT was not associated with any significant cognitive deficits in people with treatment-resistant schizophrenia across global cognition, attention, language, visuospatial function, and executive function domains. The majority of studies…
Read articles from ASCP Corner
Letters to the Editor
Letter to the Editor
Mental Health Assessment and Psychosocial Intervention in Maternal-Fetal Interventions
November 18, 2024
In discussing a recent JCP letter to the editor, Akerson et al recommend that centers for fetal diagnosis and treatment include a social worker who can provide psychosocial assessment,…
Commentaries
Commentary
Lower Risk of Cardiovascular Disorders in Antidepressant-Treated Women Veterans: Encouraging Findings but Concerns Remain
May 7, 2025
Comments on a study by Sumner et al that followed 609,546 women veterans for a mean of 8.8 years to look at associations of antidepressants with incident CVD.
Commentary
Eating Disorders Among Transgender and Gender Diverse People: Qualitative Analysis of Reddit Threads
March 10, 2025
This subreddit analysis characterizes the body dissatisfaction and desire to eliminate gendered physical characteristics that transgender and gender diverse (TGD) people with eating disorders experience. Many on the subreddit…
More JCP Articles
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report
August 13, 2025
A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in bipolar type I disorder.
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report
August 13, 2025
A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in schizophrenia.
Original Research
Effects of Alcohol Use on Cognition in Individuals With Neurocognitive Disorders
August 6, 2025
In a memory clinic cohort of patients with neurocognitive disorders, alcohol related cognitive impairment resulted in specific deficits involving cognitive control during delayed recall task.
Original Research
Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression
July 30, 2025
The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.
Original Research
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
July 30, 2025
Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
Original Research
Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders
July 16, 2025
Adolescents with bipolar disorder and those with MDD had significantly lower Klotho levels compared with the control group; those with bipolar disorder had the highest MMP-9 levels, followed by…
